Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin and HIPEC and Intraoperative Brachytherapy for Rhabdomyosarcoma and Undifferentiated Sarcomas in Children
NCT03111069Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 1, open-label trial of doxorubicin in rhabdomyosarcoma (RMS) and undifferentiated sarcoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 day. Planned start Aug 2018; status: withdrawn.
02
Drugs
doxorubicin
03
Conditions
rhabdomyosarcoma (RMS)undifferentiated sarcoma
Beyond the preview
Go deeper on NCT03111069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111069.